DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

Phase 4

Completed

Conditions: ADHD
Attention Deficit Hyperactivity Disorder

Interventions: Drug: Atomoxetine and OROS Methylphenidate

First Posted Date: 2008-01-04

Last Posted Date: 2012-11-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 94

Registration Number: NCT00585910

Locations: 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States

Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS

Phase 4

Completed

Conditions: ADHD

Interventions: Drug: memantine hydrochloride

First Posted Date: 2008-01-04

Last Posted Date: 2012-06-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT00586573

Locations: 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

Phase 4

Completed

Conditions: ADHD
Attention Deficit Hyperactivity Disorder

Interventions: Drug: Methylphenidate Transdermal System
Drug: Placebo

First Posted Date: 2008-01-04

Last Posted Date: 2012-11-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT00586157

Locations: 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States

Memantine and Cognitive Dysfunction in Bipolar Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2008-01-04

Last Posted Date: 2017-10-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 72

Registration Number: NCT00586066

Locations: 🇺🇸
Asher Depression Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Cedars Sinai Department of Psychiatry, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Naproxen for the Prevention of HO After Complex Elbow Trauma

Phase 4

Withdrawn

Conditions: Heterotopic Ossification

Interventions: Drug: Naproxen

First Posted Date: 2008-01-04

Last Posted Date: 2012-03-21

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00586365

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Photochemical Tissue Bonding

Phase 2

Completed

Conditions: Basal Cell Carcinoma
Squamous Cell Carcinoma
Atypical Nevus

Interventions: Procedure: tissue bonding
Procedure: sutures

First Posted Date: 2008-01-04

Last Posted Date: 2009-04-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT00586040

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2008-01-04

Last Posted Date: 2017-09-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 57

Registration Number: NCT00585962

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

The Role of Splinting in Fingertip Injuries

Withdrawn

Conditions: Injury Distal to Flexor and Extensor Tendon Insertions

First Posted Date: 2007-12-24

Last Posted Date: 2015-12-30

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00580164

Locations: 🇺🇸
Mass General Hospital, Boston, Massachusetts, United States

Smoking Cessation Intervention for Thoracic Patients

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Smoking cessation counseling
Drug: varenicline

First Posted Date: 2007-12-24

Last Posted Date: 2018-10-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 49

Registration Number: NCT00580398

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Phase 1

Completed

Conditions: Myelodysplasia

Interventions: Drug: Bortezomib
Drug: Lenalidomide

First Posted Date: 2007-12-24

Last Posted Date: 2012-03-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 23

Registration Number: NCT00580242

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy